Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Name: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
Published: 2019
License: Public Domain

Dan Zandberg · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

head and neck squamous cell carcinoma (hnscc), anti-pd1 antibody, anti-ctla4 antibody, anti-lag3 antibody, tumor infiltrating lymphocyte (til), interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Related documents